Conditions: Carcinoma, Hepatocellular
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 134
Healthy volunteers: no

Brief summary:
This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients

Detailed description:

Arms:
arm 1: Phase I dose escalation and phase II using dose determined in phase I arm 2: Twice daily dosing in phase II

Interventions: intervention 1: Sorafenib intervention 2: BIBF 1120
Intervention descriptions: intervention 1: 400 mg twice daily intervention 2: Twice daily

Protocol document: